← ANALYST RATINGS · TIPRANKS
NewAmsterdam Pharma Company (NAMS): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $52.71, the highest $60.00, the lowest $42.00. The average is +165.8% from the last price of $19.83.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $20.00 → $19.50−2.5% | Hold | −1.7% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $20.50 → $20.00−2.4% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $20.00 → $19.50−2.5% | Hold | −1.7% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $21.00 → $20.50−2.4% | Hold | +3.4% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $20.50 → $20.00−2.4% | Hold | +0.9% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $55.00 | Buy | +177.4% | Reiterated | 15.10.26on TipRanks 07:45 | +2.8%next day −2.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $21.00 → $20.00−4.8% | Hold | +0.9% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $22.00 → $21.00−4.5% | Hold | +5.9% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $21.50 → $20.50−4.7% | Hold | +3.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $21.50 → $20.50−4.7% | Hold | +3.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $22.00 → $20.50−6.8% | Hold | +3.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $21.00 → $20.00−4.8% | Hold | +0.9% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.50 → $21.00−10.6% | Hold | +5.9% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $24.50 → $22.00−10.2% | Hold | +10.9% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $24.00 → $21.50−10.4% | Hold | +8.4% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.50 → $21.50−8.5% | Hold | +8.4% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $24.00 → $22.00−8.3% | Hold | +10.9% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.50 → $21.00−10.6% | Hold | +5.9% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $50.00 → $42.00−16.0% | Buy | +111.8% | Reiterated | 05.10.26on TipRanks 07:16 | −2.4%next day −2.9% · 5 days −7.2% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $55.00 | Buy | +177.4% | Reiterated | 02.10.26on TipRanks Oct 5 07:40 | −4.7%next day −2.4% · 5 days −8.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.00 → $23.50+2.2% | Hold | +18.5% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.50 → $24.50+4.3% | Hold | +23.6% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $23.00 → $24.00+4.3% | Hold | +21.0% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $22.50 → $23.50+4.4% | Hold | +18.5% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.00 → $24.00+4.3% | Hold | +21.0% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $22.50 → $23.50+4.4% | Hold | +18.5% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $52.00 | Buy | +162.2% | Reiterated | 29.09.26on TipRanks 12:15 | +1.2%next day +2.3% · 5 days −8.4% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $57.00 | Buy | +187.4% | Reiterated | 22.09.26on TipRanks 08:10 | +3.3%next day −2.0% · 5 days +3.3% | ↗ |
| Name not given | — | $58.00 | Buy | +192.5% | Reiterated | 21.09.26on TipRanks Sep 22 08:05 | −1.2%next day +3.3% · 5 days +5.4% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 18.09.26on TipRanks 04:35 | +2.4%next day −1.2% · 5 days −0.9% | ↗ |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $50.00 | Buy | +152.1% | Reiterated | 08.09.26on TipRanks 06:50 | +1.5%next day −10.6% · 5 days −16.3% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $48.00 | Buy | +142.1% | Reiterated | 07.08.26on TipRanks 17:50 | +0.1%next day −1.0% · 5 days −3.8% | ↗ |
| Unknown Analyst | Citi | $55.00 | Buy | +177.4% | Reiterated | 06.08.26on TipRanks 07:01 | +1.1%next day +0.4% · 5 days −4.8% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $60.00 | Buy | +202.6% | Reiterated | 04.08.26on TipRanks 07:45 | −1.6%next day −0.3% · 5 days +0.4% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $37.00 → $38.00+2.7% | Hold | +91.6% | Reiterated | 07.05.26on TipRanks May 11 09:10 | +12.8%next day +10.3% · 5 days +3.6% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $45.00 | Buy | +126.9% | Reiterated | 07.05.26on TipRanks May 8 07:30 | +12.8%next day +10.3% · 5 days +3.6% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 07.05.26on TipRanks 14:35 | +12.8%next day +10.3% · 5 days +3.6% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $49.00 | Buy | +147.1% | Reiterated | 19.02.26on TipRanks 08:05 | −2.9%next day +2.0% · 5 days −1.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering NewAmsterdam Pharma Company
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $53.00 at a price of $23.20 (+128.4%); now: $53.00 at $19.83 (+167.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 8 | 9 | 12 | 11 |
| Buy | 7 | 6 | 4 | 1 | 2 | 2 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.49 (from $-0.62 to $-0.33). Last quarter: $-0.52.
Sales
Next quarter’s sales estimate — $8M (from $0M to $24M). Last quarter: $4M.
Best top-analyst consensus in the sector · Healthcare
About NewAmsterdam Pharma Company
- CEO: Michael Harvey Davidson Facp.
- Employees: 100
- Gooimeer 2-35, Naarden, NH, 1411 DC, NL
- www.newamsterdampharma.com
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Data from the stock’s TipRanks forecast page, read 76 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗